MS patients have an imbalance of Effector and Regulatory cells which causes nerve damage. The solution is a Novel small molecule STAT3 inhibitor, LLL12B, that improves Effector/Regulator cell balance. LLL12b significantly suppresses the disease progression in three murine MS model. There is a great opportunity for this solution as MS is prevalent in 300 people per every 100,000 in the US and is onset in the age range of 20-40.
Many diseases are managed or treated by invasive IVs or frequent injections. We are all familiar with the difficult routines of chemotherapy to treat cancer and insulin injections to manage diabetes. This is particularly true for diseases that impact the eye. All of us will experience some form of age-related vision loss, with some of the leading causes with no cure shown here, including diabetic retinopathy, glaucoma, and macular degeneration. Loss of vision greatly reduces quality of life, and impacts daily activities we take for granted including reading and driving. Most of these diseases require chronic local treatment to prevent permanent blindness, and the only option may include frequent intraocular injections.
Early indication of fluid accumulation to trigger adjustments to medical therapy preventing costly readmissions and avoiding life threatening complications.
There is a growing aging population and there is no cure or treatment for Alzheimer's. The only current drugs are palliative. The Synapse Enhancer enhances the integrity of the synapse which improves cognitive function and can delay/halt neurodegeneration. It could be utilized for a many diseases such as, Alzheimer's, ALS, Parkinson's, Huntington's, Traumatic Brain Injury, Stroke, Epilepsy, Depression, Neuropathic Pain Disorders, and Addiction.